Skip to content

Home
Company
Clinical Research
Technology
Partnerships
News
Contact

Home
Company
Clinical Research
Technology
Partnerships
News
Contact

Publications, Papers and Posters

Presentation: Intratumoral INT230-6 injection into solid tumors kills tumors and induces immune cell infiltration leading to abscopal responses and prolonged disease control in multiple refractory cancer types (NCT 03058289)

November 19, 2019

Presentation made at SITC 2019 by Dr. Jacob Thomas, Assistant Professor of Medicine, University of Southern California

Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory (OncoImmunology)

July 17, 2019

Article published online July 16, 2019 in the journal OncoImmunology

Poster: INT230-6, a novel intratumoral (IT) formulation demonstrated a favorable safety profile during injections into a variety of refractory deep and superficial tumors with evidence of tumor regression and immune activation

May 17, 2019

Poster presented at ASCO 2019

Poster: Phase 1/2 Evaluation of Intratumoral INT230-6 for the Treatment of Solid Tumors

November 5, 2018

Poster presented at SITC 2018

Poster: Phase 1/2 Evaluation of Intratumoral INT230-6 for the Treatment of Solid Tumors

October 6, 2018

Poster presented at ESMO 2018

Poster: Phase 1/2 trial evaluating intratumoral administration of INT230-6 alone and in combination with an anti-PD1 antibody for advanced malignancies

June 6, 2018

Poster presented at ASCO 2018

Poster: Tumor cell death caused by INT230-6 induces protective T cell immunity

April 6, 2017

Poster presented at AACR 2017

Poster: Intratumoral injection of INT230-6 induces protective T cell immunity

November 6, 2016

Poster presented at SITC 2016

Poster: A novel immunotherapy, INT230-6, is able to induce high rates of complete and durable response in mice through a cytotoxic T-cell-dependent mechanism

April 18, 2016

Poster presented at AACR 2016

Poster: Novel Drug, INT230-6 shows strong synergy with anti-PD-1 Antibodies and can induce high complete response rates with T-cell memory response in a colon cancer mouse model

November 11, 2015

Poster presented at SITC 2015

« Previous Page1 Page2 Page3 Next »

Privacy Policy

Menu

Privacy Policy

© 2022 Intensity Therapeutics. All rights reserved.

Linkedin Twitter